Wandercraft Signs 12 Calvin 40 Customers as Renault Plans 350 Humanoids
Wandercraft said on 4 September 2026 that twelve blue chip firms ordered its Calvin 40 industrial humanoid, while Renault Group targets 350 unit deployments within eighteen months. The release marks commercial traction beyond medical exoskeleton roots.
What changed
Wandercraft announced on 4 September 2026 that twelve blue chip customers signed for Calvin 40, its industrial humanoid built on the same self balancing stack as its medical exoskeletons. Sectors named include automotive, logistics, retail, healthcare, and defense. The company said it is ramping production to meet demand.
Renault Group, an existing partner, plans to deploy 350 humanoids within eighteen months, giving a scale anchor for factory buyers evaluating reliability and uptime requirements.
Why it matters
Humanoid headlines often cite pilots. A disclosed customer count plus an OEM volume target gives procurement teams a reference for RFQ timing and service level expectations. Wandercraft emphasizes success rate and uptime for hazardous or ergonomically difficult tasks, starting in manufacturing.
The Renault linkage also shows automakers treating humanoids as line assets, not only R&D props, which pressures integrators to standardize safety cases and spare parts logistics.
Who is affected
Plant operations leaders in automotive and logistics, robotics distributors comparing Calvin 40 against Agility Digit and Unitree offerings, and insurers pricing humanoid deployments on factory floors.
What to do next
If you issue humanoid RFPs this quarter, require named reference sites with task level mean time between interventions, not only joint press releases.
What to watch
Whether Wandercraft publishes deployment counts by task type and whether Renault's 350 unit plan hits stated timelines without narrowing task scope.
Sources
- Primary. GlobeNewswire, Wandercraft secures 12 Calvin 40 customers (4 September 2026). Customer count, sectors, Renault 350 unit plan.
- Secondary. Wandercraft, Corporate platform overview (September 2026). Product positioning and medical to industrial lineage.